Showing 13,301 - 13,310 of 13,355
In this paper we study the effect of reference pricing on pharmaceutical prices and expenditures when generic entry is endogenously determined. We develop a Salop-type model where a brand-name producer competes with generic producers in terms of prices. In the market there are two types of...
Persistent link: https://www.econbiz.de/10011203036
Persistent link: https://www.econbiz.de/10010563797
In Spain, the social security (i.e., the public health system) budget relays on the local administrations of every region. From this budget, a very important amount of money goes to finance, totally or partially and medicines for people. If the administrations do not take this issue seriously,...
Persistent link: https://www.econbiz.de/10008564360
We provide a method allowing identification of margins in an oligopoly price competition game when prices may not be freely chosen in some markets, for example due to regulation. We use our identification strategy to study the effects of regulatory constraints in the pharmaceutical industry. We...
Persistent link: https://www.econbiz.de/10010898239
We provide a method allowing identification of margins in an oligopoly price competition game when prices may not be freely chosen in some markets, for example due to regulation. We use our identification strategy to study the effects of regulatory constraints in the pharmaceutical industry. We...
Persistent link: https://www.econbiz.de/10010760344
This paper attempts to demonstrate that the present governance challenges facing policy makers in the WTO and its member states with regard to the public health crises in developing countries cannot be simply overcome by modifying the TRIPs Agreement. One argument pursued in this paper is that...
Persistent link: https://www.econbiz.de/10010784348
pharmaceuticals. We challenge this orthodox view and show, to the contrary, that the pace of innovation often is faster in a world …
Persistent link: https://www.econbiz.de/10005666872
We analyze the impact of national pharmaceutical regulation on the launch delay of new chemical entities approved by the EMEA’s centralized procedure. We find that direct price control regimes have a significantly negative impact on the launch timing. These results cannot be found when...
Persistent link: https://www.econbiz.de/10005755111
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10005756608
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 % of total pharmaceutical sale in Norway. With use of a unique natural policy experiment in Norway, this paper examines to what extent the identity of the...
Persistent link: https://www.econbiz.de/10004967612